Thanks again for your interest in the Kasey Altman hackathon to find the best next treatment for this rare cancer patient. This is our weekly update (#15), especially for those who were unable to join us in person on our last two meetings on September 9 and 16.
Kasey is in San Diego and following a healthy lifestyle while she waits for the delayed start (which has now slipped to late November from late October) of her treatment in a clinical trial of a personalized neoantigen vaccine. The delay is due to a complicated supply chain with many vendors and handoffs, overseen by UCSD. (Please see the recordings for more details.)
The prioritization event for Kasey’s contingency plans (should she have a recurrence after her personalized vaccine) with clinicians and researchers was held on Sunday, September 12. Two main insights were (1) to develop a strategy that sits on top of specific treatment recommendations, and (2) a consensus on combining an immunotherapy (such as a checkpoint inhibitor) with a treatment targeted on Kasey’s mutations (such as B7H3).
Please see the recordings for more details.
In Closing: Our Request
Any thoughts on accelerating the personalized vaccine production timeline?
Kasey Altman, Delsee Altman, Lupe Montes, and Brad Power